A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $251 to $300
Oppenheimer Upgrades Argenx SE to Outperform From Perform, $546 Price Target
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,200
Gilead Sciences (GILD) Receives a Buy From TD Cowen
Oppenheimer Upgrades Argenx SE(ARGX.US) to Buy Rating, Announces Target Price $546
Piper Sandler Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $313
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
IQVIA Holdings Price Target Raised to $251.00/Share From $235.00 by Baird
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,166
IQVIA Hldgs Analyst Ratings
Evercore ISI Adjusts Price Target on IQVIA Holdings to $270 From $230, Maintains Outperform Rating
TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $500 From $450, Maintains Buy Rating
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,030, Maintains Buy Rating
Buy Rating Affirmed for Vertex Pharmaceuticals Amid Strategic Acquisition and Strong CF Franchise Outlook
Piper Sandler Reaffirms Their Buy Rating on Biogen (BIIB)
Piper Sandler Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344